Salah Eddine O Kacimi, Caroline Dehais, Loïc Feuvret, Olivier Chinot, Catherine Carpentier, Charlotte Bronnimann, Elodie Vauleon, Apolline Djelad, Elizabeth Cohen-Jonathan Moyal, Olivier Langlois, Mario Campone, Mathilde Ducloie, Georges Noel, Stefania Cuzzubbo, Luc Taillandier, Carole Ramirez, Nadia Younan, Philippe Menei, Frédéric Dhermain, Christine Desenclos, François Ghiringhelli, Veronique Bourg, Damien Ricard, Thierry Faillot, Romain Appay, Emeline Tabouret, Lucia Nichelli, Bertrand Mathon, Alice Thomas, Suzanne Tran, Franck Bielle, Agusti Alentorn, J Bryan Iorgulescu, Pierre-Yves Boëlle, Karim Labreche, Khê Hoang-Xuan, Marc Sanson, Ahmed Idbaih, Dominique Figarella-Branger, François Ducray, Mehdi Touat
PURPOSE: Patients with IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma (O3IDHmt/Codel ) benefit from adding alkylating agent chemotherapy to radiotherapy (RT). However, the optimal chemotherapy regimen between procarbazine, 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), and vincristine (PCV) and temozolomide (TMZ) remains unclear given the lack of randomized trial data comparing both regimens. METHODS: The objective was to assess the overall survival (OS) and progression-free survival (PFS) associated with first-line PCV/RT versus TMZ/RT in patients newly diagnosed with O3IDHmt/Codel ...
October 2, 2024: Journal of Clinical Oncology